Clinical Trials Logo

Metastatic Breast Cancer clinical trials

View clinical trials related to Metastatic Breast Cancer.

Filter by:

NCT ID: NCT00333047 Completed - Clinical trials for Metastatic Breast Cancer

Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy

Start date: July 2002
Phase: Phase 2/Phase 3
Study type: Interventional

Therapeutic interventions for patients with metastatic breast cancer are aimed at prolonging survival and improving the quality of life. The objective of this trial is to assess if an initial chemotherapy followed by an endocrine therapy leads to a longer disease-free interval as compared to chemotherapy alone.

NCT ID: NCT00322374 Completed - Clinical trials for Metastatic Breast Cancer

Phase I Combination w/ Epirubicin

Start date: August 2006
Phase: Phase 1
Study type: Interventional

Tumor response information was obtained for all participants who received at least 2 cycles of study drug, underwent requisite baseline and on-treatment disease assessments and had at least one post-treatment assessment. Tumor response assessment in evaluable participants was done according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

NCT ID: NCT00319618 Completed - Clinical trials for Metastatic Breast Cancer

Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer

Start date: June 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if combination therapy of weekly Taxotere™ with Iressa™ will increase the objective responses in measurable leasions in metastatic breast cancer

NCT ID: NCT00316199 Completed - Clinical trials for Metastatic Breast Cancer

Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer

Start date: April 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the response rate to a gemcitabine-paclitaxel combination administered on a 3-weekly schedule in Chinese patients with unresectable, locally recurrent breast cancer or metastatic breast cancer.

NCT ID: NCT00313170 Completed - Clinical trials for Metastatic Breast Cancer

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg

FINDER II
Start date: May 30, 2006
Phase: Phase 2
Study type: Interventional

This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.

NCT ID: NCT00307229 Completed - Clinical trials for Metastatic Breast Cancer

Adenovirus Encoding Rat HER-2 in Patients With Metastatic Breast Cancer (AdHER2.1)

Start date: March 2006
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of adenovector expressing rat Her-2/neu in patients with metastatic or locally recurrent breast cancer.

NCT ID: NCT00305448 Completed - Clinical trials for Metastatic Breast Cancer

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mg

FINDER I
Start date: March 2006
Phase: Phase 2
Study type: Interventional

This study will assess the relationship between fulvestrant dose and efficacy, and determine the dosing regimen as a second line therapy for Japanese postmenopausal women with oestrogen receptor positive advanced breast cancer.

NCT ID: NCT00303108 Completed - Clinical trials for Metastatic Breast Cancer

Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).

NCT ID: NCT00281697 Completed - Clinical trials for Metastatic Breast Cancer

A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)

Start date: February 2006
Phase: Phase 3
Study type: Interventional

This phase III, multicenter, randomized, placebo-controlled, blinded trial is designed to evaluate the efficacy and safety of bevacizumab when combined with standard chemotherapy compared with chemotherapy alone in subjects with previously treated metastatic breast cancer.

NCT ID: NCT00274469 Completed - Clinical trials for Metastatic Breast Cancer

A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer

FIRST
Start date: February 6, 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.